Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The mdm2 gene encodes several protein isoforms with different molecular weights (p90, p80,
p76
and p57). MDM2 p90 (usually considered to be the major MDM2 protein) binds to and inactivates
P53
. We have recently shown that growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with
P53
down-regulation. In this work, we analyzed the expression pattern of MDM2 proteins in three human breast cancer cell lines by western blotting with anti-MDM2 antibodies. We found a prominent expression of MDM2 p57 protein in cell lines which have non-functional
P53
protein (T47D and MDA-MB-231) as compared to the p90, p80 isoforms, whereas p90 was the major protein isoform in MCF-7 cells that contain functional
P53
protein. When MCF-7 cells were treated with 100 nM of progesterone, MDM2 p90 was inhibited but the highly expressed MDM2 p57 isoform was not. The inhibition of MDM2 p90 protein by progesterone was abrogated in MCF-7 cells transfected with a
P53
expressing vector. To our knowledge, this is the first report linking progesterone-induced growth inhibition with down-regulation of the MDM2 protein. We present evidence that reestablishing of
P53
expression by transient transfection of
P53
cDNA in these cells enhances the expression level of MDM2 p90 isoform. The data indicate that expression of MDM2 p90 is regulated through a
P53
-dependent pathway in response to progesterone.
...
PMID:Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels. 1956 11
Vitiligo is characterized by a patchy loss of inherited skin color affecting approximately 0.5% of individuals of all races. Despite the absence of the protecting pigment and the overwhelming evidence for hydrogen peroxide (H(2)O(2))-induced oxidative stress in the entire epidermis of these patients, there is neither increased photodamage/skin aging nor a higher incidence for sun-induced nonmelanoma skin cancer. Here we demonstrate for the first time increased DNA damage via 8-oxoguanine in the skin and plasma in association with epidermal up-regulated phosphorylated/acetylated
p53
and high levels of the
p53
antagonist
p76
(MDM2). Short-patch base-excision repair via hOgg1, APE1, and polymerasebeta DNA repair is up-regulated. Overexpression of Bcl-2 and low caspase 3 and cytochrome c levels argue against increased apoptosis in this disease. Moreover, we show the presence of high epidermal peroxynitrite (ONOO(-)) levels via nitrotyrosine together with high nitrated
p53
levels. We demonstrate by EMSA that nitration of
p53
by ONOO(-) (300 x 10(-6) M) abrogates DNA binding, while H(2)O(2)-oxidized
p53
(10(-3) M) enhances DNA binding capacity and prevents ONOO(-)-induced abrogation of DNA binding. Taken together, we add a novel reactive oxygen species to the list of oxidative stress inducers in vitiligo. Moreover, we propose up-regulated wild-type
p53
together with
p76
(MDM2) as major players in the control of DNA damage/repair and prevention of photodamage and nonmelanoma skin cancer in vitiligo.
...
PMID:Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. 1964 Nov 44
Several caspase-cleaved forms of the retinoblastoma protein have been described. Here, we compared the effect of full-length Rb versus the truncated
p76
(Rb) and p100(Rb) proteins on cell death regulation in five human cell lines. Interestingly, we observed that
p76
(Rb) triggers cell death in all tested cell lines and that p100(Rb) protects two cell lines against etoposide or TNF-alpha-induced cell death, whereas full-length Rb has no apoptotic effect. These results show that truncated forms of Rb can have specific activities in the regulation of cell death. They also suggest that caspase cleavage of Rb should not be simply assimilated to a degradation process. Finally, we show that cell death induced by
p76
(Rb) is Bax-dependent and is diminished by Bcl-2 overexpression or by caspase inhibition and that p100(Rb) could inhibit cell death by decreasing both
p53
stability and caspase activity.
...
PMID:The p76(Rb) and p100(Rb) truncated forms of the Rb protein exert antagonistic roles on cell death regulation in human cell lines. 2063 63
Under basal growth conditions,
p53
function is tightly controlled by the members of MDM family, MDM2 and MDM4. The Mdm2 gene codes, in addition to the full-length p90(MDM2), for a short protein,
p76
(MDM2) that lacks the
p53
-binding domain. Despite this property and at variance with p90(MDM2), this protein acts positively toward
p53
, although the molecular mechanism remains elusive. Here, we report that
p76
(MDM2) antagonizes MDM4 inhibitory function. We show that
p76
(MDM2) possesses intrinsic ubiquitinating and degrading activity, and through these activities controls MDM4 levels. Furthermore, the presence of
p76
(MDM2) decreases the association of MDM4 with
p53
and p90(MDM2), and antagonizes
p53
degradation by the heterodimer MDM4/p90(MDM2). The
p76
(MDM2)-mediated regulation of MDM4 occurs in the cytoplasm, under basal growth conditions. Conversely, upon DNA damage, phosphorylation of MDM4Ser403 dissociates
p76
(MDM2) and prevents MDM4 degradation. The overall negative control of MDM4 by
p76
(MDM2) reflects on
p53
function as
p76
(MDM2) impairs MDM4-mediated inhibition of
p53
activity. In agreement with the positive role of
p76
(MDM2) toward
p53
, the
p76
(MDM2)/p90(MDM2) ratio significantly decreases in a group of thyroid tumor samples compared with normal counterparts. Overall, these findings reveal a new mechanism in the control of
p53
basal activity that may account for the distinct sensitivity of tissues to stress signals depending on the balance among MDM proteins. Moreover, these data suggest an oncosuppressive function for a product of the Mdm2 gene.
...
PMID:Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity. 2069 59
MDM-2 is an oncoprotein that seems to function, at least in part, by interacting with the
p53 protein
and modulating its tumor-suppressing activity. The MDM-2 gene codes for p57, p74,
p76
, p85, and p90 proteins. Overexpression of only the p90 MDM-2 protein has been reported in sarcomas showing MDM-2 gene amplification. In addition, post-transcriptional mechanisms have been demonstrated to play a role in the expression of MDM-2 proteins. We investigated MDM-2 gene amplification, mRNA and protein levels in various cases of sarcomas. We found MDM-2 gene amplification in 12 (26%) of 46 cases of sarcoma: 11 of 13 cases of liposarcoma and 1 of 6 cases of malignant fibrous histiocytoma. The MDM-2 amplification correlated with the presence of elevated levels of mRNA and protein in the liposarcomas. In sarcomas other than liposarcomas, mRNA was overexpressed in 7 (30%) of 23 cases, without MDM-2 amplification. In 15 (62.5%) of 24 cases of sarcoma and in 1 case of lipoma the MDM-2 protein was overexpressed as shown by Western blot analysis. Interestingly, p57 not p90 was the most commonly overexpressed MDM-2 protein. These data indicate that the molecular abnormalities affecting MDM-2 expression in cases of sarcoma include transcriptional, post-transcriptional, and gene dosage (amplification) mechanisms. Furthermore, our findings suggest that MDM-2 p57 protein may be as important as p90 in the pathogenesis of human sarcomas.
...
PMID:Molecular abnormalities of mdm-2 in human sarcomas. 2155 29
<< Previous
1
2